Recently, the State Drug Administration approved the listing of the 1.1 class innovative drug Senyu Ning Shen Tablets declared by Guangdong Siji Pharmaceutical Co.
The drug carried out a randomized, double-blind, placebo-controlled multi-center clinical trial, the clinical trial study results show that the main efficacy index (HAMD-17 score reduction rate ≥ 50% is effective) efficiency group comparison, the test group efficacy than the placebo group.
The drug benefits Qi and nourishes Yin, calms the mind and relieves depression. It is suitable for mild to moderate depression with Chinese medical evidence of Qi and Yin deficiency. The launch of this drug provides another treatment option for depression patients.
The drug carried out a randomized, double-blind, placebo-controlled multi-center clinical trial, the clinical trial study results show that the main efficacy index (HAMD-17 score reduction rate ≥ 50% is effective) efficiency group comparison, the test group efficacy than the placebo group.
The drug benefits Qi and nourishes Yin, calms the mind and relieves depression. It is suitable for mild to moderate depression with Chinese medical evidence of Qi and Yin deficiency. The launch of this drug provides another treatment option for depression patients.
